AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26189608 — intervention group
Group type: EXPERIMENTAL
Intervention: Single bout of low-intensity exercise with coffee (CS)
Number of subjects: 7
Study 26160892 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-monitoring of blood glucose (SMBG)
Number of subjects: 18
Study 26160892 — intervention group
Group type: COMPARATOR
Intervention: Urine monitoring
Number of subjects: 18
Study 22918663 — intervention group
Group type: EXPERIMENTAL
Intervention: Full mouth non‐surgical periodontal therapy followed by open flap surgery
Number of subjects: 12
Study 21239119 — intervention group
Group type: EXPERIMENTAL
Intervention: MDD+ smokers
Number of subjects: 101
Study 21239119 — intervention group
Group type: COMPARATOR
Intervention: MDD- smokers
Number of subjects: 101
Study 18474764 — intervention group
Group type: EXPERIMENTAL
Intervention: Blacks
Number of subjects: 333
Study 16114063 — intervention group
Group type: EXPERIMENTAL
Intervention: Clover phytoestrogens 240 mg daily for 2 weeks
Number of subjects: 40
Study 16114063 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 14526951 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary excretion rates measured in microg U g(‐1) creatinine for 1997 and 1999.
Number of subjects: 33
Study 10971313 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous diltiazem (loading dosage and constant infusion)
Number of subjects: 10
Study 10971313 — intervention group
Group type: COMPARATOR
Intervention: Oral lovastatin (20 mg)
Number of subjects: 10
Study 8617086 — intervention group
Group type: EXPERIMENTAL
Intervention: PGI2 (Prostacyclin) at a dose of 2 to 12 ng/kg/min, IV, infused continuously for 48 h
Number of subjects: 16
Study 8617086 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 1548451 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine 178 mg
Number of subjects: 15
Study 1548451 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine doses (100 mg, 56 mg, 32 mg, 18 mg, 10 mg)
Number of subjects: 15
Study 1548451 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 2984846 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 micrograms anti-Rh intramuscularly
Number of subjects: 14
Study 2984846 — intervention group
Group type: COMPARATOR
Intervention: 0.28 ml of Rh-positive red cells (challenge)
Number of subjects: 14
Study 31553222 — intervention group
Group type: EXPERIMENTAL
Intervention: Absorb everolimus-eluting bioresorbable vascular scaffold (BVS)
Number of subjects: 0
Study 31553222 — intervention group
Group type: COMPARATOR
Intervention: Cobalt chromium everolimus-eluting stents (EES)
Number of subjects: 0
Study 28901839 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-based educational training based on the PRECEDE-PROCEED model
Number of subjects: 80
Study 28901839 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 80
Study 27505205 — intervention group
Group type: EXPERIMENTAL
Intervention: Images of negative health outcomes
Number of subjects: 711
Study 27505205 — intervention group
Group type: EXPERIMENTAL
Intervention: Images of positive health outcomes
Number of subjects: 711
Study 27505205 — intervention group
Group type: COMPARATOR
Intervention: No image control
Number of subjects: 711
Study 25033105 — intervention group
Group type: EXPERIMENTAL
Intervention: BuMA (PLGA-polymer with electro-grafting base layer sirolimus-eluting stent)
Number of subjects: 80
Study 25033105 — intervention group
Group type: COMPARATOR
Intervention: EXCEL (PLA-polymer sirolimus-eluting stent)
Number of subjects: 80
Study 23141144 — intervention group
Group type: EXPERIMENTAL
Intervention: Clobazam at dosages ≤2.0 mg/kg/day (≤80 mg/day)
Number of subjects: 267
Study 23141144 — intervention group
Group type: EXPERIMENTAL
Intervention: Clobazam for ≥12 months
Number of subjects: 267
Study 23141144 — intervention group
Group type: EXPERIMENTAL
Intervention: Clobazam for ≥1 year
Number of subjects: 267
Study 23141144 — intervention group
Group type: EXPERIMENTAL
Intervention: Clobazam
Number of subjects: 267
Study 20979934 — intervention group
Group type: EXPERIMENTAL
Intervention: Probenecid (PRB) co-administered with Mizoribine (MZR)
Number of subjects: 12
Study 20979934 — intervention group
Group type: COMPARATOR
Intervention: Mizoribine (MZR) alone
Number of subjects: 12
Study 18981007 — intervention group
Group type: EXPERIMENTAL
Intervention: CHOP-R (cyclophosphamide, doxorubicin, vincristine, prednisone, and rituximab) for three cycles followed by 90Y-ibritumomab tiuxetan (RIT) and extended rituximab
Number of subjects: 60
Study 18981007 — intervention group
Group type: EXPERIMENTAL
Intervention: CHOP-R followed by RIT
Number of subjects: 60
Study 15864879 — intervention group
Group type: EXPERIMENTAL
Intervention: Rupatadine 10 mg once daily
Number of subjects: 249
Study 15864879 — intervention group
Group type: COMPARATOR
Intervention: Cetirizine 10 mg
Number of subjects: 249
Study 12798283 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose 100 mg/kg
Number of subjects: 0
Study 12798283 — intervention group
Group type: COMPARATOR
Intervention: Glucose 500 mg/kg
Number of subjects: 0
Study 12798283 — intervention group
Group type: COMPARATOR
Intervention: Glucose 50 g
Number of subjects: 0
Study 12798283 — intervention group
Group type: COMPARATOR
Intervention: Placebo (23.7 mg saccharin)
Number of subjects: 0
Study 10482985 — intervention group
Group type: EXPERIMENTAL
Intervention: Axl expression present (19 out of 54 cases, 35%)
Number of subjects: 54
Study 10482985 — intervention group
Group type: COMPARATOR
Intervention: Axl expression absent (not specified how many cases)
Number of subjects: 54
Study 8961362 — intervention group
Group type: EXPERIMENTAL
Intervention: 44 Gy in 16 daily fractions of radiation therapy (RT)
Number of subjects: 186
Study 8144848 — intervention group
Group type: EXPERIMENTAL
Intervention: GH treatment alone
Number of subjects: 18
Study 8144848 — intervention group
Group type: COMPARATOR
Intervention: Clinical follow‐up (group A)
Number of subjects: 18
Study 8144848 — intervention group
Group type: EXPERIMENTAL
Intervention: GH + LHRHa treatment
Number of subjects: 18
Study 3529772 — intervention group
Group type: EXPERIMENTAL
Intervention: 5000 IU of heparin + 0.5 mg dihydroergotamine (HDHE) s.c. every 12 hours
Number of subjects: 86
Study 3529772 — intervention group
Group type: COMPARATOR
Intervention: 5000 IU of heparin (LDH) s.c. every 8 hours
Number of subjects: 86
Study 28700428 — intervention group
Group type: EXPERIMENTAL
Intervention: Collection of lymph nodes (LNs) into nodal basin-specific containers
Number of subjects: 56
Study 28700428 — intervention group
Group type: COMPARATOR
Intervention: Simple labeling of lymph nodes on the nonrandomized side
Number of subjects: 56
Study 28700428 — intervention group
Group type: EXPERIMENTAL
Intervention: Processing of additional adipose tissue
Number of subjects: 56
Study 27362270 — intervention group
Group type: EXPERIMENTAL
Intervention: Early medical abortion provided by nurse-midwives
Number of subjects: 1180
Study 27362270 — intervention group
Group type: COMPARATOR
Intervention: Standard procedure (early medical abortion provided by physicians)
Number of subjects: 1180
Study 24622114 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical examination finding: Peripheral edema
Number of subjects: 1376
Study 24622114 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical examination finding: Pulmonary rales
Number of subjects: 1376
Study 24622114 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical examination finding: Jugular venous distension
Number of subjects: 1376
Study 24622114 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical examination finding: Third heart sound
Number of subjects: 1376
Study 22331336 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed cord clamping (DCC)
Number of subjects: 51
Study 22331336 — intervention group
Group type: COMPARATOR
Intervention: Immediate cord clamping (ICC)
Number of subjects: 51
Study 20683456 — intervention group
Group type: EXPERIMENTAL
Intervention: 30g fibre of potatoes (FP)
Number of subjects: 14
Study 20683456 — intervention group
Group type: EXPERIMENTAL
Intervention: 30g wrinkle pea starch (WPS)
Number of subjects: 14
Study 20683456 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 14
Study 20683456 — intervention group
Group type: EXPERIMENTAL
Intervention: 375g Lactobacillus acidophilus (LC1) yoghurt
Number of subjects: 14
Study 19167589 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg QD
Number of subjects: 339
Study 19167589 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg QD
Number of subjects: 339
Study 15938887 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified base-type pontics
Number of subjects: 60
Study 15938887 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified ridge lap pontics
Number of subjects: 60
Study 15938887 — intervention group
Group type: COMPARATOR
Intervention: Ovata pontics
Number of subjects: 60
Study 15938887 — intervention group
Group type: EXPERIMENTAL
Intervention: Before tooth preparation and 3 months after fixed prosthesis insertion
Number of subjects: 60
Study 15320851 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin receptor blockers (ARBs)
Number of subjects: 0
Study 15320851 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination ARB/ACE inhibitor therapy
Number of subjects: 0
Study 15320851 — intervention group
Group type: COMPARATOR
Intervention: ACE inhibitor therapy alone
Number of subjects: 0
Study 9477387 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional formula (NF)
Number of subjects: 12
Study 9477387 — intervention group
Group type: COMPARATOR
Intervention: Standard test meal (ST)
Number of subjects: 12
Study 9477387 — intervention group
Group type: COMPARATOR
Intervention: Glucose test meal (GT)
Number of subjects: 12
Study 8029088 — intervention group
Group type: EXPERIMENTAL
Intervention: Buserelin, 1800 micrograms/day as nasal spray
Number of subjects: 12
Study 8029088 — intervention group
Group type: EXPERIMENTAL
Intervention: Triptorelin Depot, 3.75 mg/every 4 weeks i.m.
Number of subjects: 12
Study 2567345 — intervention group
Group type: COMPARATOR
Intervention: SKF 39393 (selective D-1 dopamine receptor agonist) at daily doses ranging from 3.2 to 32 mg/kg over treatment intervals of one to seven weeks.
Number of subjects: 0
Study 2567345 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 0
Study 1153447 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol self-administration (8 drinks of ethanol, 89.12 g total)
Number of subjects: 4
Study 1153447 — intervention group
Group type: COMPARATOR
Intervention: Orange juice self-administration (8 drinks of orange juice)
Number of subjects: 4
Study 30629160 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted therapy including mineralocorticoid receptor antagonists, statins, ACE inhibitors and/or receptor blockers, and cardiac rehabilitation.
Number of subjects: 230
Study 30629160 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted therapy
Number of subjects: 230
Study 30629160 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 230
Study 29066163 — intervention group
Group type: EXPERIMENTAL
Intervention: Eculizumab
Number of subjects: 125
Study 29066163 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 125
Study 26173635 — intervention group
Group type: EXPERIMENTAL
Intervention: CRT-D in patients with LVEF ≤30% (n = 1100)
Number of subjects: 1783
Study 26173635 — intervention group
Group type: EXPERIMENTAL
Intervention: CRT-D in patients with LVEF >30% (n = 683)
Number of subjects: 1783
Study 26173635 — intervention group
Group type: EXPERIMENTAL
Intervention: Each 5% increment in LVEF
Number of subjects: 1783
Study 26173635 — intervention group
Group type: EXPERIMENTAL
Intervention: CRT-D treatment effect by LVEF interaction
Number of subjects: 1783
Study 23215626 — intervention group
Group type: EXPERIMENTAL
Intervention: Focused ultrasound stimulation
Number of subjects: 50
Study 23215626 — intervention group
Group type: COMPARATOR
Intervention: Conventional acupuncture
Number of subjects: 50
Study 21520154 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of biomarkers PSMA, PSGR, and PCA3 detected by quantitative real-time PCR in post-PM urine sediment.
Number of subjects: 154
Study 18316236 — intervention group
Group type: EXPERIMENTAL
Intervention: Stuttering patients with abnormal movements (AMs)
Number of subjects: 85
Study 18316236 — intervention group
Group type: EXPERIMENTAL
Intervention: Involuntary movements concurrent to speech
Number of subjects: 85
Study 18316236 — intervention group
Group type: EXPERIMENTAL
Intervention: Involuntary movements not concurrent to speech
Number of subjects: 85
Study 18316236 — intervention group
Group type: EXPERIMENTAL
Intervention: Conscious control of movement during speech
Number of subjects: 85
Study 16569543 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy (CRT)
Number of subjects: 537
Study 16569543 — intervention group
Group type: COMPARATOR
Intervention: Standard medical therapy
Number of subjects: 537
Study 12764406 — intervention group
Group type: EXPERIMENTAL
Intervention: Olmesartan medoxomil (20 mg/day)
Number of subjects: 440
Study 12764406 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine (5 mg/day)
Number of subjects: 440
Study 12764406 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 440
Study 10684842 — intervention group
Group type: EXPERIMENTAL
Intervention: Vancomycin eye drops applied to the medial canthus with closed lids
Number of subjects: 53
Study 10684842 — intervention group
Group type: COMPARATOR
Intervention: Vancomycin eye drops applied to the lower cul de sac with open lids (conventional method)
Number of subjects: 53
Study 9444445 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alfa (480 million U over 6 months)
Number of subjects: 82
Study 9444445 — intervention group
Group type: COMPARATOR
Intervention: No drug treatment (Control)
Number of subjects: 82
Study 8127929 — intervention group
Group type: EXPERIMENTAL
Intervention: Moclobemide (300‐600 mg/d)
Number of subjects: 115
Study 8127929 — intervention group
Group type: COMPARATOR
Intervention: Maprotiline (75‐150 mg/d)
Number of subjects: 115
Study 3426682 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium carbimide (50 mg)
Number of subjects: 10
Study 3426682 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 28985255 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol 1 mg orally twice-daily (maximum of 14 doses)
Number of subjects: 245
Study 28985255 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 245
Study 27177609 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored assistive technology intervention
Number of subjects: 240
Study 27177609 — intervention group
Group type: COMPARATOR
Intervention: Standard care group
Number of subjects: 240
Study 26283079 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced restriction protocol (no recommendations regarding sleeping position)
Number of subjects: 456
Study 26283079 — intervention group
Group type: COMPARATOR
Intervention: Care as usual (postoperative restrictions including advice to sleep in a supine position for the first 8 weeks)
Number of subjects: 456
Study 26283079 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced restriction protocol
Number of subjects: 456
Study 23510450 — intervention group
Group type: EXPERIMENTAL
Intervention: 17 G/ 35 mm (standard) needle
Number of subjects: 21
Study 23510450 — intervention group
Group type: COMPARATOR
Intervention: 20 G/ 35 mm (thin) needle
Number of subjects: 21
Study 20883866 — intervention group
Group type: EXPERIMENTAL
Intervention: EUS-guided ethanol lavage
Number of subjects: 12
Study 20883866 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up CT
Number of subjects: 12
Study 18602599 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted therapy (specific molecules not detailed)
Number of subjects: 0
Study 18602599 — intervention group
Group type: COMPARATOR
Intervention: Cytotoxic chemotherapy (not explicitly detailed)
Number of subjects: 0
Study 16736333 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic therapy (intravenous for 2 days, followed by oral for 10 days)
Number of subjects: 252
Study 16736333 — intervention group
Group type: COMPARATOR
Intervention: Surgery (open or laparoscopic appendectomy)
Number of subjects: 252
Study 12803270 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib 200 mg
Number of subjects: 90
Study 12803270 — intervention group
Group type: EXPERIMENTAL
Intervention: Rofecoxib 50 mg
Number of subjects: 90
Study 12803270 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 11775892 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (10 mg-20 mg, three times daily before labor, orally every 6 hours during labor)
Number of subjects: 64
Study 11775892 — intervention group
Group type: COMPARATOR
Intervention: Control (no Nifedipine during labor)
Number of subjects: 64
Study 8649570 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate 200 mg/day
Number of subjects: 181
Study 8649570 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate 400 mg/day
Number of subjects: 181
Study 8649570 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate 600 mg/day
Number of subjects: 181
Study 8649570 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate
Number of subjects: 181
Study 8649570 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 181
Study 1517944 — intervention group
Group type: EXPERIMENTAL
Intervention: Diosmectite
Number of subjects: 59
Study 1517944 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study 7036292 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy with 5-fluorouracil (10 mg/kg/day) and BCNU (40 mg/m2/day) for 5 days, administered eight times in 6‐8 week intervals.
Number of subjects: 103
Study 7036292 — intervention group
Group type: COMPARATOR
Intervention: Control group (no chemotherapy).
Number of subjects: 103
Study 30239491 — intervention group
Group type: EXPERIMENTAL
Intervention: 30-min nap after a reference night
Number of subjects: 13
Study 30239491 — intervention group
Group type: EXPERIMENTAL
Intervention: 30-min nap after a partial sleep deprivation night
Number of subjects: 13
Study 30239491 — intervention group
Group type: EXPERIMENTAL
Intervention: 30-min nap after fatigue induced by KST
Number of subjects: 13
Study 29705869 — intervention group
Group type: EXPERIMENTAL
Intervention: Suvorexant 10 mg
Number of subjects: 40
Study 29705869 — intervention group
Group type: EXPERIMENTAL
Intervention: Suvorexant 20 mg
Number of subjects: 40
Study 29705869 — intervention group
Group type: EXPERIMENTAL
Intervention: Suvorexant 40 mg
Number of subjects: 40
Study 29705869 — intervention group
Group type: EXPERIMENTAL
Intervention: Suvorexant 80 mg
Number of subjects: 40
Study 29705869 — intervention group
Group type: EXPERIMENTAL
Intervention: Suvorexant 100 mg
Number of subjects: 40
Study 29705869 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 29705869 — intervention group
Group type: EXPERIMENTAL
Intervention: Suvorexant (all doses)
Number of subjects: 40
Study 26809022 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid therapy (esomeprazole 20 mg and amoxicillin 1000 mg twice daily for 14 days with the addition of clarithromycin 500 mg and tinidazole 500 mg twice daily for the final 7 days)
Number of subjects: 196
Study 26809022 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid therapy
Number of subjects: 196
Study 26809022 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual clarithromycin and metronidazole resistance
Number of subjects: 196
Study 24188287 — intervention group
Group type: EXPERIMENTAL
Intervention: Instructed emotion regulation using reappraisal while watching a sadness-inducing film clip
Number of subjects: 152
Study 24188287 — intervention group
Group type: COMPARATOR
Intervention: Spontaneous emotion regulation (no specific instructions)
Number of subjects: 152
Study 21723359 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymidylate synthase (TS) 2R→3R polymorphism
Number of subjects: 1595
Study 21723359 — intervention group
Group type: EXPERIMENTAL
Intervention: Serine hydroxymethyltransferase (SHMT1) 1420C→T polymorphism
Number of subjects: 1595
Study 21723359 — intervention group
Group type: EXPERIMENTAL
Intervention: 5,10-methylenetetrahydrofolate reductase (MTHFR) 677C→T polymorphism
Number of subjects: 1595
Study 21723359 — intervention group
Group type: EXPERIMENTAL
Intervention: Mood assessment using the depression subscale of the Symptom Checklist 90
Number of subjects: 1595
Study 21503180 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine 5 mg/kg
Number of subjects: 20
Study 21503180 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine 10 mg/kg
Number of subjects: 20
Study 21503180 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine 15 mg/kg
Number of subjects: 20
Study 21503180 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 17173248 — intervention group
Group type: EXPERIMENTAL
Intervention: CTGF mRNA expression in diabetic nephropathy (DN)
Number of subjects: 0
Study 17173248 — intervention group
Group type: EXPERIMENTAL
Intervention: TGF-beta 1 mRNA expression in diabetic nephropathy (DN)
Number of subjects: 0
Study 17173248 — intervention group
Group type: EXPERIMENTAL
Intervention: Type IV collagen mRNA expression in diabetic nephropathy (DN)
Number of subjects: 0
Study 17173248 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of CTGF, TGF-beta 1, and type IV collagen mRNA expressions
Number of subjects: 0
Study 12717205 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus + Sirolimus
Number of subjects: 361
Study 12717205 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus + MMF
Number of subjects: 361
Study 11026396 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 g of glucose
Number of subjects: 20
Study 11026396 — intervention group
Group type: COMPARATOR
Intervention: Artificially sweetened beverage
Number of subjects: 20
Study 9232256 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus (FK506) with methotrexate
Number of subjects: 70
Study 9232256 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporine with methotrexate
Number of subjects: 70
Study 1587426 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral erythromycin (500 mg)
Number of subjects: 30
Study 1587426 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral erythromycin (three times weekly for 1 month)
Number of subjects: 30
Study 1587426 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral erythromycin
Number of subjects: 30
Study 2871286 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed Doppler ultrasound scanning
Number of subjects: 20